In parallel with these clinical investigations, we integrated transcriptomic data from pretreatment biopsy samples of patients who received these novel treatments, enabling a comprehensive molecular characterization of HR+/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.